U.S. Machinery Stock News

NasdaqGS:IIIV
NasdaqGS:IIIVSoftware

Modest Q1 Profit At I3 Verticals (IIIV) Tests Bullish Earnings Acceleration Narratives

i3 Verticals (IIIV) opened fiscal Q1 2026 with revenue of US$52.7 million and basic EPS of US$0.03, while net income excluding extra items came in at US$0.6 million. The company has seen quarterly revenue move between US$46.2 million and US$61.7 million over the past two years, with basic EPS ranging from a loss of US$0.58 to a profit of US$0.54. This latest print lands in the middle of its recent earnings range and keeps the focus firmly on how margins are evolving from here. See our full...
NasdaqGS:FLNC
NasdaqGS:FLNCElectrical

Fluence Energy (FLNC) Valuation Check After Earnings Jump Revenue Guidance And Backlog Update

Fluence Energy (FLNC) is in focus after first quarter earnings showed revenue of US$475.23 million compared with US$186.79 million a year earlier, alongside a wider net loss and reaffirmed full year revenue guidance. See our latest analysis for Fluence Energy. The latest earnings release and reaffirmed guidance arrived after a volatile stretch for the stock, with a 7 day share price return of a 36.82% decline and a year to date share price return of a 15.52% decline. At the same time, the 1...
NasdaqGS:SYNA
NasdaqGS:SYNASemiconductor

Synaptics (SYNA) Revenue Growth With Continued EPS Loss Tests Bullish Turnaround Narratives

Synaptics (SYNA) just posted Q2 2026 results with revenue of US$302.5 million and a basic EPS loss of US$0.38, while net income excluding extra items came in at a loss of US$14.8 million, keeping profitability under pressure. Over the past few quarters, revenue has moved from US$267.2 million in Q2 2025 to US$266.6 million in Q3, US$282.8 million in Q4, US$292.5 million in Q1 2026 and now US$302.5 million. Over the same period, EPS has swung from a small profit of US$0.05 in Q2 2025 to losses...
NYSE:COP
NYSE:COPOil and Gas

ConocoPhillips (COP) Margin Compression Challenges Bullish Earnings Growth Narrative

ConocoPhillips (COP) has just wrapped up FY 2025 with Q4 revenue of US$13.7b and basic EPS of US$1.17, alongside net income excluding extra items of US$1.4b. This puts fresh numbers on the table for investors watching its earnings power. Over recent quarters, the company has seen revenue move from US$14.7b and EPS of US$1.90 in Q4 2024 to a FY 2025 trajectory that includes US$16.9b of revenue and EPS of US$2.23 in Q1 2025, before settling at the latest Q4 run rate. With trailing 12 month net...
NasdaqGS:MU
NasdaqGS:MUSemiconductor

Micron’s US$24b Singapore Fab Raises AI Promise And Valuation Questions

Micron Technology has broken ground on a new US$24b advanced wafer fabrication plant in Singapore. The facility is focused on next generation NAND production aimed at rising AI driven data storage demand. The project includes plans for advanced automation, sustainability features, and workforce development in a key semiconductor hub. For investors tracking Micron Technology (NasdaqGS:MU), this Singapore build out comes at a time when the stock is trading around US$394.69. The company has...
NYSE:CUZ
NYSE:CUZOffice REITs

Cousins Properties (CUZ) Q4 FFO Loss Of US$358.9 Million Reinforces Bearish Office REIT Narratives

Cousins Properties (CUZ) has wrapped up FY 2025 with Q4 revenue of US$261.2 million and a basic EPS loss of US$0.02, alongside a funds from operations loss of US$358.9 million that puts the quarter firmly in the red for shareholders. Over recent periods, the company has seen revenue move from US$223.3 million in Q4 2024 to US$248.4 million in Q1 2025 and US$238.5 million in Q2 2025 before reaching US$245.6 million in Q3 2025, while quarterly basic EPS ranged from earnings of US$0.12 in Q1...
NasdaqGM:ARDX
NasdaqGM:ARDXBiotechs

How IBSRELA Trial Expansion And New 2042 Patent At Ardelyx (ARDX) Has Changed Its Investment Story

Ardelyx recently announced dosing of the first patient in ACCEL, a Phase 3 trial of IBSRELA (tenapanor) in adults with chronic idiopathic constipation, while also securing a new U.S. patent extending oral formulation protection for IBSRELA and XPHOZAH to 2042. The combination of advancing IBSRELA into a large new indication and lengthening patent protection may reshape how long Ardelyx’s medicines can remain differentiated in the market. With the new 2042 formulation patent as a backdrop,...